Actress Busy Philipps revealed in August 2026 that she was diagnosed with a grade 2 oligodendroglioma, a rare and typically slow-growing malignant brain tumor, after an unexpected finding on a whole-body MRI. Her diagnosis led to two brain surgeries and has brought new attention to a cancer many people have never heard of. Actress Busy Philipps has shared that she was diagnosed with a grade 2 oligodendroglioma after imaging unexpectedly revealed a lesion in her brain.
The 47-year-old actress had no classic warning signs such as seizures when the tumor was discovered. After further evaluation, she underwent surgery in March 2026 to remove the mass, followed by a second operation because of a postoperative complication. Today, Philipps does not require chemotherapy or radiation therapy and is being monitored with regular brain scans.
Photo: Depositphotos
Her experience offers an opportunity not only to explain what oligodendroglioma is, but also to explore the complicated questions surrounding incidental cancer detection, advanced imaging, and what it means to live with a malignant brain tumor that can nevertheless have a relatively favorable prognosis.
Who Is Busy Philipps?
Elizabeth Jean “Busy” Philipps was born on June 25, 1979, in Oak Park, Illinois, and grew up in the Chicago area. She adopted the nickname “Busy” as a child and later carried it into her professional career. After high school, Philipps studied theater at Loyola Marymount University in Los Angeles while beginning to pursue acting professionally.
Her breakthrough came with the cult television series Freaks and Geeks, where she played Kim Kelly. She later became widely known for roles in Dawson’s Creek, ER, Cougar Town, and films including White Chicks, Made of Honor, and He’s Just Not That Into You. Over the years, Philipps has built a public identity that extends well beyond acting, including work as an author, television host, podcaster, and advocate.
Career Philosophy and Public Persona
Philipps has become known for her candid humor and unusually open approach to discussing both professional and personal experiences. Through interviews, social media, her memoir, and her podcast Busy Philipps Is Doing Her Best, she has frequently spoken about the pressure placed on women in entertainment, body image, mental health, motherhood, and the expectation to appear as though everything is under control. Rather than presenting a carefully polished public image, Philipps has often emphasized authenticity and the idea of simply “doing her best” rather than pursuing perfection.
That same openness became part of the way she discussed her brain tumor diagnosis in 2026. Her account included not only the medical details of surgery and recovery but also the fear and uncertainty that came with unexpectedly learning that she had a malignant brain tumor.
Advocacy and Health-Related Work
Long before her oligodendroglioma diagnosis, Philipps had used her public platform to speak about women’s health, mental health, access to healthcare, and other issues affecting women and families. Her 2018 memoir, This Will Only Hurt a Little, explored experiences including trauma, loss, relationships, motherhood, and navigating difficult periods of her life. Following her brain tumor diagnosis, Philipps has increasingly framed her experience around the importance of health advocacy: paying attention to changes in one’s body, asking questions, seeking additional medical opinions when appropriate, and feeling empowered to participate actively in healthcare decisions.
Her experience has particular resonance because her tumor was not discovered after the development of dramatic neurological symptoms. Instead, it was found unexpectedly on imaging.
The Whole-Body MRI That Found Her Brain Tumor
One of the most discussed aspects of Philipps’ story is how her oligodendroglioma was discovered. In February 2026, she underwent a Prenuvo whole-body MRI despite not having symptoms typically associated with a brain tumor, such as seizures. The scan unexpectedly detected a lesion in her right frontal lobe. A dedicated brain MRI and subsequent evaluation ultimately led to surgery and the diagnosis of a grade 2 oligodendroglioma.
Philipps has said that she almost did not undergo the scan and that her primary care physician had told her she did not medically need it. In her individual case, however, the imaging identified the tumor before she developed obvious neurological symptoms.
Should Everyone Get a Whole-Body MRI?
Philipps’ experience inevitably raises a much larger question: should healthy people undergo whole-body MRI screening to look for cancers before symptoms develop? The answer is considerably more complicated than her individual experience might suggest.
Whole-body MRI can identify unexpected abnormalities, including some potentially important tumors. However, routine whole-body MRI screening is not currently recommended for the general asymptomatic population. One of the major concerns is the frequency of incidental findings abnormalities that appear on imaging but may never cause illness. These findings can lead to additional scans, biopsies, procedures, anxiety, costs, and in some cases treatment for abnormalities that might otherwise never have become clinically significant. This creates the risks of false-positive findings, overdiagnosis, and overtreatment. Philipps’ case therefore should not be interpreted as evidence that everyone needs a whole-body MRI.
Instead, it illustrates the complexity of cancer screening: a test that may provide extraordinary benefit to one individual does not automatically become an appropriate population-wide screening strategy. Decisions about advanced imaging should be individualized and discussed with clinicians who understand a person’s symptoms, medical history, family history, risk factors, and the potential benefits and harms of additional testing. Philipps herself has also acknowledged that access to elective advanced imaging is a privilege that is not universally available. The broader lesson from her experience is therefore less about one particular scan and more about health awareness, self-advocacy, and informed conversations between patients and their healthcare teams.
Busy Philipps’ Diagnosis and Treatment Journey
In February 2026, Philipps’ whole-body MRI revealed an unexpected lesion in the right frontal lobe of her brain. A subsequent dedicated brain MRI confirmed the abnormality and led to further evaluation. On March 2, 2026, neurosurgeon Dr. John Golfinos at NYU Langone performed an approximately five-hour operation to remove the 2.6-centimeter mass.
Pathologic examination identified the tumor as a grade 2 oligodendroglioma. Philipps later required a second operation to manage a postoperative complication. Importantly, she did not require immediate chemotherapy or radiation following surgery. As of her August 2026 disclosure, Philipps was undergoing active surveillance with regular MRI scans. Her neuro-oncologist, Dr. Alexandra Miller, described oligodendroglioma as having one of the most favorable prognoses among malignant gliomas. However, a favorable prognosis does not mean the disease can be forgotten. Oligodendrogliomas can recur or progress over time, which makes long-term surveillance an important part of care.
What Is Oligodendroglioma?
Oligodendroglioma is a rare primary tumor of the central nervous system and belongs to a broader group of tumors known as gliomas. Modern diagnosis is based not only on what the tumor looks like under the microscope but also on its molecular characteristics. To be classified as an oligodendroglioma, the tumor must have two defining molecular features:
- An IDH mutation
- A 1p/19q codeletion
These molecular alterations distinguish oligodendroglioma from other diffuse gliomas and are essential for establishing the diagnosis. Oligodendrogliomas most commonly develop in the cerebral hemispheres, particularly the frontal lobes, although they can occur elsewhere in the central nervous system.
Grade 2 Oligodendroglioma: What Does It Mean?
Oligodendrogliomas are currently classified as CNS WHO grade 2 or grade 3. There is no grade 4 oligodendroglioma in the modern classification system. A grade 2 oligodendroglioma is generally slow-growing. However, “low-grade” does not mean that the tumor is harmless. These tumors infiltrate surrounding brain tissue and may eventually recur or progress, sometimes many years after the initial diagnosis and treatment. Grade 3 oligodendrogliomas have more aggressive pathological characteristics and generally require more intensive treatment.
How Common Is Oligodendroglioma?
Oligodendroglioma is uncommon compared with other primary brain tumors. According to Philipps’ treating neuro-oncologist, approximately 1,100 to 1,300 people in the United States are diagnosed with oligodendroglioma each year. Its rarity means that many patients and families may never have heard of the disease before receiving a diagnosis. High-profile disclosures such as Philipps’ can therefore bring unusual public attention to a relatively uncommon cancer.
What Are the Symptoms of Oligodendroglioma?
Because oligodendrogliomas often grow slowly, symptoms may develop gradually. In some people, as in Philipps’ case, the tumor may be discovered incidentally before obvious neurological symptoms appear. Possible symptoms include:
- Seizures
- Persistent or worsening headaches
- Changes in memory or concentration
- Personality or behavioral changes
- Speech difficulties
- Vision changes
- Problems with balance or coordination
- Weakness or numbness affecting one side of the body
The exact symptoms depend heavily on where the tumor develops in the brain. Many of these symptoms are far more commonly caused by conditions other than cancer. However, new, persistent, or progressive neurological symptoms should be medically evaluated.
How Is Oligodendroglioma Diagnosed?
The diagnostic process typically begins with neurological assessment and brain imaging.
MRI
Magnetic resonance imaging (MRI) is the main imaging technique used to evaluate a suspected brain tumor. MRI can show the tumor’s size, location, relationship to surrounding brain structures, and other radiological characteristics. Advanced techniques such as perfusion imaging, diffusion imaging, or MR spectroscopy may provide additional information in selected cases. However, imaging alone cannot provide the definitive modern diagnosis of oligodendroglioma.
Surgery or Biopsy
Tumor tissue is required for accurate diagnosis. Whenever safely possible, surgery provides both tissue for diagnosis and an opportunity to remove as much of the tumor as possible. A neuropathologist then evaluates the tissue and performs molecular testing, including assessment for IDH mutation and 1p/19q codeletion. These molecular findings are now fundamental to the classification of oligodendroglioma.
How Is Oligodendroglioma Treated?
Treatment is individualized based on the tumor’s grade, location and molecular profile, the extent of surgical resection, the patient’s age and overall health, and the expected risk of recurrence or progression.
Surgery
When feasible, maximal safe resection is usually the first step. The goal is to remove as much tumor as possible without causing unacceptable neurological impairment. Surgery also provides tissue for the histologic and molecular testing needed to establish the diagnosis.
Active Surveillance
Not every patient with a grade 2 oligodendroglioma requires immediate additional treatment after surgery. For selected patients with favorable features and extensive tumor resection, doctors may recommend active surveillance rather than immediately starting radiation or chemotherapy. This generally includes regular neurological assessments and serial brain MRIs. Philipps is currently following this approach.
Radiation Therapy
Radiation therapy may be recommended when the risk of recurrence or progression is higher, including in some patients with residual tumor or other unfavorable clinical features. It is also an important component of treatment for many higher-risk or grade 3 oligodendrogliomas.
Chemotherapy
When postoperative systemic treatment is indicated, chemotherapy is often combined with radiation therapy. One established chemotherapy regimen used in oligodendroglioma is PCV, which consists of:
Procarbazine + lomustine (CCNU) + vincristine
For higher-risk grade 2 tumors, long-term clinical trial data support radiation followed by PCV as an important treatment approach. Treatment decisions remain individualized, and the optimal strategy depends on both clinical and molecular features.
Clinical Trials and Emerging Therapies
Clinical trials remain particularly important in neuro-oncology, including for patients with recurrent or progressive disease. As the biology of IDH-mutant gliomas becomes better understood, treatment is increasingly moving toward molecularly informed and targeted approaches.
What Is the Prognosis for Oligodendroglioma?
Oligodendroglioma generally has a more favorable prognosis than many other diffuse malignant gliomas. The National Cancer Institute reports an overall five-year relative survival rate of approximately 79.5%, although this figure includes different grades and clinical situations and cannot predict an individual patient’s outcome.
Prognosis depends on several factors, including:
- Tumor grade
- Age at diagnosis
- Tumor location
- Extent of surgical resection
- Molecular characteristics
- Neurological function
- Response to treatment
- Grade 2 oligodendrogliomas can follow a prolonged clinical course, with some patients living for many years after diagnosis.
However, most require long-term follow-up because recurrence or progression can occur even after an initially successful treatment.
Why Busy Philipps’ Story Matters
Philipps’ case is unusual because her tumor was discovered incidentally rather than after the development of classic symptoms such as seizures. She has since encouraged people, particularly women, to advocate for themselves, ask questions, and take concerns about their health seriously. She has also acknowledged that access to elective whole-body imaging is a privilege not available to everyone. Her experience should not, however, be interpreted as evidence that everyone needs routine whole-body MRI screening.
For people without symptoms or established risk factors, decisions about screening and imaging should be made with healthcare professionals and should consider both potential benefits and the possibility of incidental findings that can lead to additional testing or procedures. The broader message from Philipps’ story is about health awareness and self-advocacy, rather than one specific screening test.
Living With Oligodendroglioma
For many people with oligodendroglioma, cancer care continues long after surgery. Even patients who do not require immediate chemotherapy or radiation may undergo MRI surveillance for years because these tumors can recur slowly. That period of observation can carry its own psychological burden. Regular scans may offer reassurance while also bringing uncertainty about whether the disease will eventually return. Philipps has spoken openly about the emotional impact of her diagnosis and recovery, helping make visible a part of cancer care that is sometimes overlooked: living with a malignancy that may be treatable and slow-growing, but still requires ongoing surveillance.
You Can Also Read Mark Ruffalo and Brain Tumor: How He Went Against, How He Survived, and More by OncoDaily
Written by Aharon Tsaturyan, MD, Editor at OncoDaily Intelligence Unit
FAQ
What type of brain tumor did Busy Philipps have?
Busy Philipps was diagnosed with a grade 2 oligodendroglioma, a rare type of glioma that typically grows relatively slowly. Modern oligodendrogliomas are characterized by an IDH mutation and 1p/19q codeletion.
Is oligodendroglioma a type of brain cancer?
Yes. Oligodendroglioma is a malignant primary brain tumor, although it generally has a more favorable prognosis and slower course than many other malignant gliomas.
What is the survival rate for grade 2 oligodendroglioma?
Grade 2 oligodendroglioma generally has a favorable long-term outlook compared with more aggressive gliomas. However, survival varies considerably depending on age, tumor location, extent of surgical removal, molecular characteristics, and treatment.
Can a grade 2 oligodendroglioma be cured?
Some patients can remain disease-free or stable for many years after treatment, particularly following extensive surgical resection. However, oligodendrogliomas can recur or progress even years later, so long-term MRI surveillance is important.
What are the first symptoms of oligodendroglioma?
Seizures are one of the most common presenting symptoms. Other possible symptoms include headaches, cognitive or personality changes, speech or vision problems, weakness, numbness, and difficulties with balance or coordination.
How did Busy Philipps discover her brain tumor?
Routine whole-body MRI is not generally recommended as cancer screening for healthy, asymptomatic people at average risk. Although it can occasionally detect important disease, it can also identify incidental abnormalities that lead to additional testing, anxiety, unnecessary procedures, and overdiagnosis.
Does oligodendroglioma always require chemotherapy or radiation?
No. Selected patients with favorable grade 2 oligodendroglioma may undergo surgery followed by active surveillance. Others may require radiation therapy, systemic therapy, or both depending on factors such as residual tumor, age, and risk of progression.
Can oligodendroglioma grow back after surgery?
Yes. Even after successful surgery, oligodendroglioma can recur or progress over time. This is why patients typically continue having periodic brain MRI scans after treatment.
What do IDH mutation and 1p/19q codeletion mean in oligodendroglioma?
They are the defining molecular features of oligodendroglioma. Under modern classification, an oligodendroglioma is an IDH-mutant and 1p/19q-codeleted diffuse glioma, making molecular testing essential for diagnosis.
